Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group

Dimitrios Rikos, Andreas A. Argyriou, Emmanouil V. Dermitzakis, Panagiotis Soldatos, Nikolaos Dimisianos, Christos Tsironis, Eleni Mavraki, Maria Chondrogianni, Aikaterini Foska, Evangelia Dimitriadou, Emmanouil Giakoumakis, Michail Vikelis, Unknown

Open source

DOI: 10.3389/fneur.2026.1912200
Published: 2026-07-29
Container: Frontiers in Neurology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fneur.2026.1912200,
  title = {Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group},
  author = {Dimitrios Rikos and Andreas A. Argyriou and Emmanouil V. Dermitzakis and Panagiotis Soldatos and Nikolaos Dimisianos and Christos Tsironis and Eleni Mavraki and Maria Chondrogianni and Aikaterini Foska and Evangelia Dimitriadou and Emmanouil Giakoumakis and Michail Vikelis and Unknown},
  year = {2026},
  journal = {Frontiers in Neurology},
  doi = {10.3389/fneur.2026.1912200},
  url = {https://doi.org/10.3389/fneur.2026.1912200}
}

RIS

TY  - JOUR
TI  - Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group
AU  - Dimitrios Rikos
AU  - Andreas A. Argyriou
AU  - Emmanouil V. Dermitzakis
AU  - Panagiotis Soldatos
AU  - Nikolaos Dimisianos
AU  - Christos Tsironis
AU  - Eleni Mavraki
AU  - Maria Chondrogianni
AU  - Aikaterini Foska
AU  - Evangelia Dimitriadou
AU  - Emmanouil Giakoumakis
AU  - Michail Vikelis
AU  - Unknown
PY  - 2026
JO  - Frontiers in Neurology
DO  - 10.3389/fneur.2026.1912200
UR  - https://doi.org/10.3389/fneur.2026.1912200
ER  -

APA

Rikos, D., Argyriou, A. A., Dermitzakis, E. V., Soldatos, P., Dimisianos, N., Tsironis, C., Mavraki, E., Chondrogianni, M., Foska, A., Dimitriadou, E., Giakoumakis, E., Vikelis, M., & Unknown (2026). Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group. Frontiers in Neurology. https://doi.org/10.3389/fneur.2026.1912200

Source records

crossref · retrieved 2026-11-10T14:07:04.474Z